APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026

19 December 2025207 pages

Choose your research edition.

Industry ResearchNeurodegenerative Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neurodegenerative Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurodegenerative Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurodegenerative Drugs market include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurodegenerative Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurodegenerative Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurodegenerative Drugs Segment by Company

TEVA

Sanofi

Novartis

Luye Pharma

Livzon Pharmaceutical

Kanghong Pharmaceutical

Jingxin Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hisun Pharmaceutical

Haisco Pharmaceutical

GlaxoSmithKline

Ark Pharmaceutical

Dongcheng Biochemicals

BORA PHARMACEUTICALS

UCB

Merck Serono

Boehringer Ingelheim

Biogen Idec

Neurodegenerative Drugs Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Drugs Segment by Application

Parkinson’s Disease

Amyotrophic Lateral Sclerosis

Huntington Disease

Alzheimer’s Disease

Neurodegenerative Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neurodegenerative Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurodegenerative Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurodegenerative Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Neurodegenerative Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurodegenerative Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Drugs industry.

Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurodegenerative Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurodegenerative Drugs Industry Trends Table 2. Neurodegenerative Drugs Industry Drivers Table 3. Neurodegenerative Drugs Industry Opportunities and Challenges Table 4. Neurodegenerative Drugs Industry Restraints Table 5. Global Neurodegenerative Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurodegenerative Drugs Revenue Share by Company (2021-2026) Table 7. Global Neurodegenerative Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Neurodegenerative Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Neurodegenerative Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Neurodegenerative Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurodegenerative Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Neurodegenerative Drugs Company, Product Type & Application Table 13. Global Neurodegenerative Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of NMDA Table 18. Significant Companies of SSRIs Table 19. Significant Companies of Dopamine Inhibitors Table 20. Global Neurodegenerative Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 21. Global Neurodegenerative Drugs Sales Volume by Type (2021-2026) & (Tons) Table 22. Global Neurodegenerative Drugs Sales Volume by Type (2027-2032) & (Tons) Table 23. Global Neurodegenerative Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Neurodegenerative Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Neurodegenerative Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neurodegenerative Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neurodegenerative Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neurodegenerative Drugs Sales Value Share by Type (2021-2026) Table 29. Global Neurodegenerative Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Parkinson’s Disease Table 31. Significant Companies of Amyotrophic Lateral Sclerosis Table 32. Significant Companies of Huntington Disease Table 33. Significant Companies of Alzheimer’s Disease Table 34. Global Neurodegenerative Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 35. Global Neurodegenerative Drugs Sales Volume by Application (2021-2026) & (Tons) Table 36. Global Neurodegenerative Drugs Sales Volume by Application (2027-2032) & (Tons) Table 37. Global Neurodegenerative Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Neurodegenerative Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Neurodegenerative Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neurodegenerative Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Neurodegenerative Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Neurodegenerative Drugs Sales Value Share by Application (2021-2026) Table 43. Global Neurodegenerative Drugs Sales Value Share by Application (2027-2032) Table 44. Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 45. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (Tons) Table 46. Global Neurodegenerative Drugs Sales Market Share by Region (2021-2026) Table 47. Global Neurodegenerative Drugs Sales by Region (2027-2032) & (Tons) Table 48. Global Neurodegenerative Drugs Sales Market Share by Region (2027-2032) Table 49. Global Neurodegenerative Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neurodegenerative Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Neurodegenerative Drugs Sales Value Share by Region (2021-2026) Table 52. Global Neurodegenerative Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Neurodegenerative Drugs Sales Value Share by Region (2027-2032) Table 54. Global Neurodegenerative Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global Neurodegenerative Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 57. Global Neurodegenerative Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 59. Global Neurodegenerative Drugs Sales Market Share by Country (2021-2026) Table 60. Global Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 61. Global Neurodegenerative Drugs Sales Market Share by Country (2027-2032) Table 62. Global Neurodegenerative Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Neurodegenerative Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Neurodegenerative Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Neurodegenerative Drugs Sales Value Market Share by Country (2027-2032) Table 66. TEVA Company Information Table 67. TEVA Business Overview Table 68. TEVA Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. TEVA Neurodegenerative Drugs Product Portfolio Table 70. TEVA Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Sanofi Neurodegenerative Drugs Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Novartis Neurodegenerative Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Luye Pharma Company Information Table 82. Luye Pharma Business Overview Table 83. Luye Pharma Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Luye Pharma Neurodegenerative Drugs Product Portfolio Table 85. Luye Pharma Recent Development Table 86. Livzon Pharmaceutical Company Information Table 87. Livzon Pharmaceutical Business Overview Table 88. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 90. Livzon Pharmaceutical Recent Development Table 91. Kanghong Pharmaceutical Company Information Table 92. Kanghong Pharmaceutical Business Overview Table 93. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 95. Kanghong Pharmaceutical Recent Development Table 96. Jingxin Pharmaceutical Company Information Table 97. Jingxin Pharmaceutical Business Overview Table 98. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 100. Jingxin Pharmaceutical Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Pfizer Neurodegenerative Drugs Product Portfolio Table 105. Pfizer Recent Development Table 106. Huahai Pharmaceutical Company Information Table 107. Huahai Pharmaceutical Business Overview Table 108. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 110. Huahai Pharmaceutical Recent Development Table 111. Hisun Pharmaceutical Company Information Table 112. Hisun Pharmaceutical Business Overview Table 113. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 115. Hisun Pharmaceutical Recent Development Table 116. Haisco Pharmaceutical Company Information Table 117. Haisco Pharmaceutical Business Overview Table 118. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 120. Haisco Pharmaceutical Recent Development Table 121. GlaxoSmithKline Company Information Table 122. GlaxoSmithKline Business Overview Table 123. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio Table 125. GlaxoSmithKline Recent Development Table 126. Ark Pharmaceutical Company Information Table 127. Ark Pharmaceutical Business Overview Table 128. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 130. Ark Pharmaceutical Recent Development Table 131. Dongcheng Biochemicals Company Information Table 132. Dongcheng Biochemicals Business Overview Table 133. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio Table 135. Dongcheng Biochemicals Recent Development Table 136. BORA PHARMACEUTICALS Company Information Table 137. BORA PHARMACEUTICALS Business Overview Table 138. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 139. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio Table 140. BORA PHARMACEUTICALS Recent Development Table 141. UCB Company Information Table 142. UCB Business Overview Table 143. UCB Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 144. UCB Neurodegenerative Drugs Product Portfolio Table 145. UCB Recent Development Table 146. Merck Serono Company Information Table 147. Merck Serono Business Overview Table 148. Merck Serono Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 149. Merck Serono Neurodegenerative Drugs Product Portfolio Table 150. Merck Serono Recent Development Table 151. Boehringer Ingelheim Company Information Table 152. Boehringer Ingelheim Business Overview Table 153. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 154. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio Table 155. Boehringer Ingelheim Recent Development Table 156. Biogen Idec Company Information Table 157. Biogen Idec Business Overview Table 158. Biogen Idec Neurodegenerative Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 159. Biogen Idec Neurodegenerative Drugs Product Portfolio Table 160. Biogen Idec Recent Development Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Neurodegenerative Drugs Distributors List Table 164. Neurodegenerative Drugs Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Neurodegenerative Drugs Product Image Figure 2. Global Neurodegenerative Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Drugs Sales (2021-2032) & (Tons) Figure 5. Global Neurodegenerative Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Neurodegenerative Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. NMDA Image Figure 10. SSRIs Image Figure 11. Dopamine Inhibitors Image Figure 12. Global Neurodegenerative Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 13. Global Neurodegenerative Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neurodegenerative Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Neurodegenerative Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neurodegenerative Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neurodegenerative Drugs Sales Value Share by Type (2021-2032) Figure 18. Parkinson’s Disease Image Figure 19. Amyotrophic Lateral Sclerosis Image Figure 20. Huntington Disease Image Figure 21. Alzheimer’s Disease Image Figure 22. Global Neurodegenerative Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global Neurodegenerative Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Neurodegenerative Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Neurodegenerative Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neurodegenerative Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Neurodegenerative Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 29. Global Neurodegenerative Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Neurodegenerative Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Neurodegenerative Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Neurodegenerative Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Neurodegenerative Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neurodegenerative Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Neurodegenerative Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Neurodegenerative Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Neurodegenerative Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Neurodegenerative Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Neurodegenerative Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Neurodegenerative Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Alzheimer’s Disease
Companies covered
  • TEVA
  • Sanofi
  • Novartis
  • Luye Pharma
  • Livzon Pharmaceutical
  • Kanghong Pharmaceutical
  • Jingxin Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hisun Pharmaceutical
  • Haisco Pharmaceutical
  • GlaxoSmithKline
  • Ark Pharmaceutical
  • Dongcheng Biochemicals
  • BORA PHARMACEUTICALS
  • UCB
  • Merck Serono
  • Boehringer Ingelheim
  • Biogen Idec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurodegenerative Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Neurodegenerative Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Neurodegenerative Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurodegenerative Drugs Market Dynamics
  1. 2.1 Neurodegenerative Drugs Industry Trends
  2. 2.2 Neurodegenerative Drugs Industry Drivers
  3. 2.3 Neurodegenerative Drugs Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Drugs Industry Restraints
3 Neurodegenerative Drugs Market by Company
  1. 3.1 Global Neurodegenerative Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Neurodegenerative Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Neurodegenerative Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurodegenerative Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Neurodegenerative Drugs Company Ranking (2024-2026)
  6. 3.6 Global Neurodegenerative Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurodegenerative Drugs Company Product Type and Application
  8. 3.8 Global Neurodegenerative Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurodegenerative Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurodegenerative Drugs Market by Type
  1. 4.1 Neurodegenerative Drugs Type Introduction
  2. 4.1.1 NMDA
  3. 4.1.2 SSRIs
  4. 4.1.3 Dopamine Inhibitors
  5. 4.2 Global Neurodegenerative Drugs Sales Volume by Type
  6. 4.2.1 Global Neurodegenerative Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neurodegenerative Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neurodegenerative Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neurodegenerative Drugs Sales Value by Type
  10. 4.3.1 Global Neurodegenerative Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neurodegenerative Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neurodegenerative Drugs Sales Value Share by Type (2021-2032)
5 Neurodegenerative Drugs Market by Application
  1. 5.1 Neurodegenerative Drugs Application Introduction
  2. 5.1.1 Parkinson’s Disease
  3. 5.1.2 Amyotrophic Lateral Sclerosis
  4. 5.1.3 Huntington Disease
  5. 5.1.4 Alzheimer’s Disease
  6. 5.2 Global Neurodegenerative Drugs Sales Volume by Application
  7. 5.2.1 Global Neurodegenerative Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurodegenerative Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neurodegenerative Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neurodegenerative Drugs Sales Value by Application
  11. 5.3.1 Global Neurodegenerative Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurodegenerative Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neurodegenerative Drugs Sales Value Share by Application (2021-2032)
6 Neurodegenerative Drugs Regional Sales and Value Analysis
  1. 6.1 Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurodegenerative Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Neurodegenerative Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Neurodegenerative Drugs Sales by Region (2027-2032)
  5. 6.3 Global Neurodegenerative Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurodegenerative Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurodegenerative Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurodegenerative Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Neurodegenerative Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurodegenerative Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Neurodegenerative Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurodegenerative Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Neurodegenerative Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurodegenerative Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurodegenerative Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurodegenerative Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Neurodegenerative Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurodegenerative Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurodegenerative Drugs Sales Value Share by Country, 2025 VS 2032
7 Neurodegenerative Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Neurodegenerative Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurodegenerative Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurodegenerative Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Neurodegenerative Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Neurodegenerative Drugs Sales by Country (2027-2032)
  6. 7.4 Global Neurodegenerative Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurodegenerative Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurodegenerative Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurodegenerative Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurodegenerative Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurodegenerative Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 TEVA
  2. 8.1.1 TEVA Company Information
  3. 8.1.2 TEVA Business Overview
  4. 8.1.3 TEVA Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 TEVA Neurodegenerative Drugs Product Portfolio
  6. 8.1.5 TEVA Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Neurodegenerative Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Luye Pharma
  20. 8.4.1 Luye Pharma Company Information
  21. 8.4.2 Luye Pharma Business Overview
  22. 8.4.3 Luye Pharma Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
  24. 8.4.5 Luye Pharma Recent Developments
  25. 8.5 Livzon Pharmaceutical
  26. 8.5.1 Livzon Pharmaceutical Company Information
  27. 8.5.2 Livzon Pharmaceutical Business Overview
  28. 8.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
  30. 8.5.5 Livzon Pharmaceutical Recent Developments
  31. 8.6 Kanghong Pharmaceutical
  32. 8.6.1 Kanghong Pharmaceutical Company Information
  33. 8.6.2 Kanghong Pharmaceutical Business Overview
  34. 8.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
  36. 8.6.5 Kanghong Pharmaceutical Recent Developments
  37. 8.7 Jingxin Pharmaceutical
  38. 8.7.1 Jingxin Pharmaceutical Company Information
  39. 8.7.2 Jingxin Pharmaceutical Business Overview
  40. 8.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
  42. 8.7.5 Jingxin Pharmaceutical Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Huahai Pharmaceutical
  50. 8.9.1 Huahai Pharmaceutical Company Information
  51. 8.9.2 Huahai Pharmaceutical Business Overview
  52. 8.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
  54. 8.9.5 Huahai Pharmaceutical Recent Developments
  55. 8.10 Hisun Pharmaceutical
  56. 8.10.1 Hisun Pharmaceutical Company Information
  57. 8.10.2 Hisun Pharmaceutical Business Overview
  58. 8.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
  60. 8.10.5 Hisun Pharmaceutical Recent Developments
  61. 8.11 Haisco Pharmaceutical
  62. 8.11.1 Haisco Pharmaceutical Company Information
  63. 8.11.2 Haisco Pharmaceutical Business Overview
  64. 8.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
  66. 8.11.5 Haisco Pharmaceutical Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Ark Pharmaceutical
  74. 8.13.1 Ark Pharmaceutical Company Information
  75. 8.13.2 Ark Pharmaceutical Business Overview
  76. 8.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
  78. 8.13.5 Ark Pharmaceutical Recent Developments
  79. 8.14 Dongcheng Biochemicals
  80. 8.14.1 Dongcheng Biochemicals Company Information
  81. 8.14.2 Dongcheng Biochemicals Business Overview
  82. 8.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
  84. 8.14.5 Dongcheng Biochemicals Recent Developments
  85. 8.15 BORA PHARMACEUTICALS
  86. 8.15.1 BORA PHARMACEUTICALS Company Information
  87. 8.15.2 BORA PHARMACEUTICALS Business Overview
  88. 8.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
  90. 8.15.5 BORA PHARMACEUTICALS Recent Developments
  91. 8.16 UCB
  92. 8.16.1 UCB Company Information
  93. 8.16.2 UCB Business Overview
  94. 8.16.3 UCB Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 UCB Neurodegenerative Drugs Product Portfolio
  96. 8.16.5 UCB Recent Developments
  97. 8.17 Merck Serono
  98. 8.17.1 Merck Serono Company Information
  99. 8.17.2 Merck Serono Business Overview
  100. 8.17.3 Merck Serono Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
  102. 8.17.5 Merck Serono Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Biogen Idec
  110. 8.19.1 Biogen Idec Company Information
  111. 8.19.2 Biogen Idec Business Overview
  112. 8.19.3 Biogen Idec Neurodegenerative Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
  114. 8.19.5 Biogen Idec Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurodegenerative Drugs Value Chain Analysis
  2. 9.1.1 Neurodegenerative Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurodegenerative Drugs Sales Mode & Process
  6. 9.2 Neurodegenerative Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurodegenerative Drugs Distributors
  9. 9.2.3 Neurodegenerative Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst